Chenodeoxycholic Acid
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Chenodeoxycholic Acid
- Chenodeoxycholic Acid: From Bile Acid Metabolism Disorders to Homozygous Familial Hypercholesterolemia
Using the drug-repurposing evaluation report template to generate this report from the supplied Evidence Pack.
Chenodeoxycholic Acid: From Bile Acid Metabolism Disorders to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Chenodeoxycholic acid (CDCA) is a naturally occurring primary bile acid; the evidence pack does not record a specific Taiwan/Finland-approved original indication for this compound, though it is historically associated with disorders of bile acid synthesis and cholesterol metabolism (e.g., gallstone dissolution, cerebrotendinous xanthomatosis). The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia, with 0 clinical trials and 1 publication currently identified, and that publication addresses a related — not the same — disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (drug.original_indications is empty; original_moa is a data gap) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 (model prediction only for this indication; the sole related publication concerns a different, mechanistically adjacent disease) |
| Finland Market Status | Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for chenodeoxycholic acid in this evidence pack (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, CDCA is a primary bile acid involved in bile acid synthesis regulation; it has been used clinically in bile acid–related and cholesterol-metabolism–related disorders, which provides a plausible mechanistic bridge to lipid/cholesterol disease states.
The single retrieved publication (PMID 25424010) is a review of cerebrotendinous xanthomatosis (CTX) — a rare autosomal-recessive lipid storage disease caused by CYP27A1 mutations that disrupts bile acid synthesis and causes cholesterol/cholestanol accumulation. CTX is treated with CDCA replacement, and the underlying biology (defective bile acid/cholesterol handling) is conceptually related to homozygous familial hypercholesterolemia (HoFH), which also involves severe disruption of cholesterol regulation. This overlap in cholesterol-pathway biology is a reasonable basis for the TxGNN model's association, but it should be treated as a mechanistic hypothesis rather than direct evidence, since no study in the pack examines CDCA specifically in HoFH patients.
Because original_moa and original_indications are not populated in this evidence pack, mechanistic linkage strength cannot be fully assessed; this is recorded as data gap DG002 and should be resolved via DrugBank/product labeling before further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25424010 | 2014 | Review | Orphanet Journal of Rare Diseases | Comprehensive review of cerebrotendinous xanthomatosis (CTX), a CYP27A1-mutation bile acid synthesis disorder causing cholestanol accumulation; CDCA is the established replacement therapy for CTX. Disease is mechanistically related to, but distinct from, homozygous familial hypercholesterolemia. |
Finland Market Information
Chenodeoxycholic acid is not currently marketed in Finland — taiwan_regulatory.market_status is "未上市" (Not Marketed) with 0 registered authorizations, so no authorization/product table is available.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug-interaction data are all recorded as data gaps in this evidence pack — TFDA labeling review, flagged DG001, is a Blocking-severity gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials for this predicted indication, no Taiwan/Finland market presence, and the single supporting publication addresses a related but distinct disease (CTX, not HoFH). Combined with a Blocking-severity data gap on TFDA labeling, the evidence base is currently insufficient to advance beyond model prediction.
To proceed, the following is needed:
- TFDA/EMA package insert (warnings, contraindications) — resolves blocking gap DG001
- DrugBank/MOA detail on CDCA's mechanism relevant to lipid metabolism — resolves gap DG002
- Dedicated clinical or preclinical studies of CDCA specifically in HoFH or related dyslipidemia populations
- DDI data query resolution (current status: not found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.